{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:04:04Z","timestamp":1768446244062,"version":"3.49.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonmyeloablative total lymphoid irradiation and antithymocyte globulin (TLI-ATG) conditioning is protective against graft-versus-host disease (GVHD), while retaining graft-versus-tumor activity across various hematologic malignancies. We report our comprehensive experience using TLI-ATG conditioning in 612 patients with hematologic malignancies who underwent allogeneic transplantation at Stanford University from 2001 to 2016. All patients received granulocyte colony-stimulating factor\u2013mobilized peripheral blood grafts and cyclosporine and mycophenolate mofetil for GVHD prophylaxis. The median age was 60 years (range, 21-78), with a median follow-up of 6.0 years (range, 1.0-16.4). Common diagnoses included acute myeloid leukemia (AML; n = 193), myelodysplastic syndrome (MDS; n = 94), chronic lymphocytic leukemia (CLL; n = 80), non-Hodgkin lymphoma (NHL; n = 175), and Hodgkin lymphoma (HL; n = 35). Thirty-four percent of patients had a comorbidity index \u22653, 30% had a high to very high disease risk index, and 56% received unrelated donor grafts, including 15% with HLA-mismatched donors. Ninety-eight percent underwent transplant in the outpatient setting, and 57% were never hospitalized from days 0 through 100. The 1-year rates of nonrelapse mortality (NRM), grade II-IV acute GVHD, and extensive chronic GVHD were 9%, 14%, and 22%, respectively. The 4-year estimates for overall and progression-free survival were 42% and 32% for AML, 30% and 21% for MDS, 67% and 43% for CLL, 68% and 45% for NHL, and 78% and 49% for HL. Mixed chimerism correlated with the risk of relapse. TLI-ATG conditioning was well tolerated, with low rates of GVHD and NRM. Durable remissions were observed across hematologic malignancies, with particularly favorable outcomes for heavily pretreated lymphomas. Several efforts are underway to augment donor chimerism and reduce relapse rates while maintaining the favorable safety and tolerability profile of this regimen.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000297","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T20:49:01Z","timestamp":1566247741000},"page":"2454-2464","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort"],"prefix":"10.1182","volume":"3","author":[{"given":"Michael A.","family":"Spinner","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-4076","authenticated-orcid":false,"given":"Vanessa E.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Tamaresis","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Science,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip W.","family":"Lavori","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Science,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-2326","authenticated-orcid":false,"given":"Samuel","family":"Strober","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"issue":"3","key":"2020021109184511700_B1","first-page":"299","article-title":"Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease","volume":"87","author":"Schetelig","year":"2002","journal-title":"Haematologica"},{"issue":"10","key":"2020021109184511700_B2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents","volume":"20","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2020021109184511700_B3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornh\u00e4user","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"2020021109184511700_B4","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021109184511700_B5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021109184511700_B6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"23","author":"Baron","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021109184511700_B7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021109184511700_B8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020021109184511700_B9","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2020021109184511700_B10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa050642","article-title":"Protective conditioning for acute graft-versus-host disease","volume":"353","author":"Lowsky","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021109184511700_B11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","article-title":"TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors","volume":"114","author":"Kohrt","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020021109184511700_B12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.4049\/jimmunol.167.4.2087","article-title":"Predominance of NK1.1+TCR \u03b1 \u03b2+ or DX5+TCR \u03b1 \u03b2+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: \u201cnatural suppressor\u201d cells","volume":"167","author":"Lan","year":"2001","journal-title":"J Immunol"},{"issue":"6","key":"2020021109184511700_B13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1083-8791(03)00108-3","article-title":"Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells","volume":"9","author":"Lan","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021109184511700_B14","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","article-title":"Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation","volume":"178","author":"Pillai","year":"2007","journal-title":"J Immunol"},{"issue":"18","key":"2020021109184511700_B15","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1182\/blood-2008-06-165506","article-title":"Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease","volume":"113","author":"Pillai","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020021109184511700_B16","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2010-08-303008","article-title":"Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism","volume":"117","author":"Leveson-Gower","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2020021109184511700_B17","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulat.ory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020021109184511700_B18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J Exp Med"},{"issue":"7","key":"2020021109184511700_B19","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/eji.201040394","article-title":"NKT cells, Treg, and their interactions in bone marrow transplantation","volume":"40","author":"Kohrt","year":"2010","journal-title":"Eur J Immunol"},{"issue":"10","key":"2020021109184511700_B20","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.bbmt.2012.03.012","article-title":"Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies","volume":"18","author":"Messina","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021109184511700_B21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","article-title":"Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society","volume":"8","author":"Baron","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2020021109184511700_B22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbmt.2014.02.023","article-title":"Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms","volume":"20","author":"Benjamin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021109184511700_B23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bmt.2015.149","article-title":"Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning","volume":"50","author":"Rezvani","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2020021109184511700_B24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/bloodadvances.2018021071","article-title":"Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation","volume":"2","author":"Spinner","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2020021109184511700_B25","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.leu.2404335","article-title":"Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"20","author":"Baron","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"2020021109184511700_B26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020021109184511700_B27","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020021109184511700_B28","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"issue":"17","key":"2020021109184511700_B29","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/bloodadvances.2017007716","article-title":"HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity","volume":"1","author":"Spinner","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"2020021109184511700_B30","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"23","key":"2020021109184511700_B31","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021109184511700_B32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020021109184511700_B33","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020021109184511700_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3667.3667","article-title":"Very high hospital admission rate after outpatient non-myeloablative allogeneic stem cell transplant using fludarabine and low dose TBI","volume":"106","author":"Bolwell","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2020021109184511700_B35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2020021109184511700_B36","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2020021109184511700_B37","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"2020021109184511700_B38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2020021109184511700_B39","first-page":"185.1","article-title":"Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"issue":"6","key":"2020021109184511700_B40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2017012104","article-title":"Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"key":"2020021109184511700_B41","first-page":"2003","article-title":"Consolidative CD8+ memory T-cell donor lymphocyte infusion augments donor chimerism with a low risk of GVHD following matched related donor hematopoietic cell transplantation","volume":"130","author":"Spinner","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2020021109184511700_B42","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1182\/blood-2011-05-356238","article-title":"Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation","volume":"118","author":"Kohrt","year":"2011","journal-title":"Blood"},{"key":"2020021109184511700_B43","doi-asserted-by":"crossref","first-page":"36.1","DOI":"10.3389\/fimmu.2015.00036","article-title":"Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies","volume":"6","author":"Di Stasi","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"2020021109184511700_B44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbrc.2008.03.076","article-title":"Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model","volume":"370","author":"Rinaldi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"2020021109184511700_B45","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/16\/2454\/1554630\/advancesadv2019000297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/16\/2454\/1554630\/advancesadv2019000297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T01:16:08Z","timestamp":1610846168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/16\/2454\/260528\/Nonmyeloablative-TLIATG-conditioning-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":45,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000297","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]}}}